Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,CTCC	SA00054166	46	F	SA00054166
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00054166	**Account Information**			**Report Notes**
Collected 02/26/2013 11:24	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 02/27/2013 12:57				

Test	Flag	Results	Unit	Reference Value	Perform Site*
Circulating Tumor Cells, Colorectal			REPORTED 02/27/2013 12:30		
Specimen		Whole Blood			MCR
Specimen ID		1060915			MCR
Order Date		27 Feb 2013 08:42			MCR
Reason for Referral					MCR
Assess for Circulating Tumor Cells					
Method					MCR
CellSearch (TM) System					
Result					MCR
Favorable, 1 circulating tumor cell/7.5 mL of blood.					
Interpretation					MCR

The results of this test are favorable (<3 circulating tumor cells/7.5 mL of blood).
These results have been interpreted by a physician.

Previous CellSearch Specimens (up to 5):

DATE	# CTCs	RESULT
01/02/2013	0	Favorable
12/02/2012	0	Favorable
11/02/2011	0	Favorable
11/02/2010	0	Favorable
11/02/2009	0	Favorable

In patients with metastatic colon cancer, favorable results are predictive of longer progression-free survival (PFS).

In one prospective multicenter study, circulating tumor cells (CTCs) were enumerated in the peripheral blood of 430 patients with metastatic colorectal cancer at baseline and after starting first-, second-, or third-line therapy. CTCs were measured using an immunomagnetic separation technique. Patients were stratified into unfavorable and favorable prognostic groups based on CTC levels of three or more or less than three CTCs/7.5 mL, respectively. Patients with unfavorable compared with favorable baseline CTCs had shorter median progression-free survival (PFS; 4.5 v 7.9 months; P = .0002) and overall survival (OS; 9.4 v 18.5 months; P < .0001). Differences persisted at 1 to 2, 3 to 5, 6 to 12, and 13 to 20 weeks after therapy. Conversion of baseline unfavorable CTCs to favorable at 3 to 5 weeks was associated with significantly longer PFS and OS compared with patients with unfavorable CTCs at both time points

Performing Site Legend on Last Page of Report

Patient Name	Patient ID	Age	Gender	Order #
SAMPLEREPORT,CTCC	SA00054166	46	F	SA00054166
Ordering Phys CLIENT,CLIENT				**DOB** 06/10/1966
Client Order # SA00054166	**Account Information**			**Report Notes**
Collected 02/26/2013 11:24	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 02/27/2013 12:57				

Test	Flag	Results	Unit	Reference Value	Perform Site*
(PFS, 6.2 v 1.6 months; P = .02; OS, 11.0 v 3.7 months; P = .0002). Among non-progressing patients, favorable compared with unfavorable CTCs within 1 month of imaging was associated with longer survival (18.8 v 7.1 months; P < .0001). Baseline and follow-up CTC levels remained strong predictors of PFS and OS after adjustment for clinically significant factors (Cohen SJ et al., J Clin Oncol. 26:3213-21, 2008.)					
Reviewed By		Angela H Zieman			MCR
Release Date		27 Feb 2013 12:29			MCR

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

TEST SITE